Truly inspired by the continuously amazing contributions by everyone, here is just some research into potential competitive HIE treatments currently being considered/developed.
It looks as though Mesenchymal Stromal Cell (MSC) Therapy is the lead runner. Apparently studies suggest that MSCs can reduce inflammation, promote tissue repair, and improve neurodevelopmental outcomes in neonates.
Where it differs from NNZ-2591 is in the mechanisms of action and delivery methods. NNZ-2591 is a small molecule administered orally, offering potential advantages in terms of ease of administration and scalability. In contrast, MSC therapy involves cell-based treatments that may require more complex procedures and infrastructure.
Basically, Mesenchymal Stromal Cell (MSC) Therapy is a stem cell therapy which means it is an injection of cells into the area of medical concern.Would you rather squirt a syringe of NNZ-2951 into a newborn's mouth or plunge a syringe full of Mesenchymal Stromal cells into a new borns soft skull multiple times???
Apologies for the potentially disturbing graphic, but I know which one I would choose if I had a choice.
Keep up the great work Neuren!
NEU Price at posting:
$13.88 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)